BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT
Delisted
BMY.RT was delisted on the 31st of December, 2020.
579 hedge funds and large institutions have $2.03B invested in Bristol-Myers Squibb Company Contingent Value Rights in 2020 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 110 increasing their positions, 217 reducing their positions, and 103 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
26% less first-time investments, than exits
New positions opened: 76 | Existing positions closed: 103
49% less repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 217
Holders
579
Holding in Top 10
12
Calls
$27.1M
Puts
$1.37M
Top Buyers
| 1 | +$66.3M | |
| 2 | +$35.6M | |
| 3 | +$21.3M | |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$18.3M |
| 5 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$17.4M |
Top Sellers
| 1 | -$37.8M | |
| 2 | -$24.2M | |
| 3 | -$20.4M | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$19.8M |
| 5 |
Renaissance Technologies
New York
|
-$18.4M |